Adverum Biotechnologies — Avalanche Biotechnologies — Merger or Acquisition (March 2016)
36 slides from Adverum Biotechnologies's merger presentation, Mar 10, 2016
Slide 1: Gaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this document regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Avalanch
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This document not constitute a solicitation of any vote or approval. In connection with the proposed transaction, Avalanche intends to file with the SEC a proxy statement of Avalanche, as well as other relevant documents concerning the proposed transaction
Slide 4: Proposed Merger with Annapurna Therapeutics
Proposed Merger with Annapurna Therapeutics Feb 1, 2016 Avalanche and Annapurna announced proposed merger: Creating a leading gene therapy company with a diverse pipeline including new assets targeting rare genetic diseases as well as AAVL’s existing ophthalmic programs Transaction Terms: Avalanche
Slide 5: Combined Company Highlights
Combined Company Highlights Diversified pipeline including 7 gene therapy product candidates in ophthalmology and rare disease ANN-001: Initiation of first-in-human trial expected in H2 2016 ANN-002: Initiation of first-in-human trial expected in 2017 Industry-leading team in gene therapy and transl
Slide 6: Avalanche Strategy
Avalanche Strategy Complete Annapurna Transaction and drive combined company programs forward Determine best path forward in wet AMD and pursue it Prioritize strategic collaboration with Regeneron- seek to leverage relationship with a leader in developing products for eye disease Conserve cash- a ke
Slide 7: Next-Generation Directed Evolution Platform
Next-Generation Directed Evolution Platform Stage 1: Create Proprietary Library of AAVs Stage 2: In Vitro and In Vivo Screening Stage 3: Selection of Tissue-Specific AAV Vectors Millions of different AAVs produced through mutagenesis In vitro cell-based testing In vivo testing Screen for ability to
Slide 8: Avalanche Product Pipeline
Avalanche Product Pipeline *Avalanche receives milestones and royalties and has an option to share development costs and profits Product Candidate Indication Stage of Development Near-Term Milestones Worldwide Commercial Rights Research Preclinical Phase 1/2 AVA-101 Wet AMD Preclinical work ongoing
Slide 9: Annapurna Product Pipeline
Product Candidate Indication Stage of Development Near-Term Milestones Worldwide Commercial Rights Research Preclinical Phase 1/2 ANN-001 A1AT Deficiency First–in-human study H2 2016 ANN-002 Hereditary Angioedema First-in-human study 2017 ANN-003 Friedreich’s Ataxia (cardio) Preclinical work ongoing
Slide 10: Annapurna Pipeline in Detail
ANN-001 for α1 Antitrypsin Deficiency (A1AT) II. ANN-002 for Hereditary Angioedema (HAE) III. ANN-003 for Friedreich’s Ataxia (FA) IV. ANN-004 for Severe Allergy Annapurna Pipeline in Detail
Slide 11: Alpha Antitrypsin (A1AT) Deficiency Overview
Alpha 1 Antitrypsin (A1AT) Deficiency Overview Mutations in SERPINA1 gene lead to A1AT deficiency Orphan disease caused by genetic mutation resulting in very low levels of A1AT A1AT protects lung from destructive neutrophil elastase Deficiencies in A1AT levels results in emphysema and early death On
Slide 12: ANN-001: Pre-Clinical Proof of Concept Studies
ANN-001: Pre-Clinical Proof of Concept Studies Intrapleural injection of AAVrh10 examined in both murine and non human primates 1High Levels of Persistent Expression of A1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh.10 Adeno-associated Virus Despite Preexisting Immunity to Common Human
Slide 13: ANN-001: Pre-Clinical Proof of Concept Studies Summary
AAVrh10 serotype selected as showed highest level of hA1AT expression in mice following intrapleural administration (compared with 25 other serotypes)1 Intrapleural administration of ~5x1012 vg/kg generated hA1AT protein levels 2.5X above therapeutic threshold in mice2 Intrapleural administration in
Slide 14: ANN-001 for A1AT Deficiency: Overview
ANN-001 for A1AT Deficiency: Overview Validated target; disease driven by mutation in single gene Shown to provide steady levels of A1AT vs peaks and troughs in preclinical studies Rationale for Gene Therapy Approach Long term expression at therapeutically relevant levels observed in wild type mice
Slide 15: Annapurna Pipeline in Detail
I. ANN-001 for α1 Antitrypsin Deficiency (A1AT) ANN-002 for Hereditary Angioedema (HAE) III. ANN-003 for Friedreich’s Ataxia (FA) IV. ANN-004 for Severe Allergy Annapurna Pipeline in Detail
Slide 16: Hereditary Angioedema (HAE) Overview
Hereditary Angioedema (HAE) Overview Life threatening genetic disease with limited therapeutic options Orphan disease caused by genetic mutation results in C1-esterase inhibitor (C1-INH) deficiency C1-INH deficiency results in excessive levels of bradykinin Bradykinin causes blood vessels to leak fl
Slide 17: Continuous delivery of C1-INH drives attack rate to near zero
Continuous delivery of C1-INH drives attack rate to near zero Gene therapy product has potential to deliver best in class profile Once weekly Daily Efficacy of prophylactic C1-INH strongly correlated with dosing interval1 1 attack every 46 days if given 1X/wk 1 attack every 132 days if given 2X/wk A
Slide 18: ANN-002 for HAE: Overview
ANN-002 for HAE: Overview Validated target: genetic disease caused by lack of C1-esterase inhibitor (C1-INH) Continuous levels of C1-INH in HAE patients reduce attack rate to near zero Rationale for Gene Therapy Approach Preliminary studies in relevant animal models suggest an AAV gene transfer vect
Slide 19: Annapurna Pipeline in Detail
I. ANN-001 for α1 Antitrypsin Deficiency (A1AT) ANN-003 for Friedreich’s Ataxia (FA) IV. ANN-004 for Severe Allergy II. ANN-002 for Hereditary Angioedema (HAE) Annapurna Pipeline in Detail
Slide 20: Friedreich's Ataxia (FA) Overview
Friedreich’s Ataxia (FA) Overview Clear unmet need with well-characterized genetic origin 1Tsou AY et al, J Neurol Sci 2011;307(1- 2):46-49 “Mortality in Friedreich Ataxia” test Normal vs. Hypertrophic heart Orphan disease caused by genetic mutation resulting in low levels of frataxin Slowly progres
Slide 21: ANN-003: Proof of Concept in Cardiac Mouse Model
ANN-003: Proof of Concept in Cardiac Mouse Model (FXN selective knockout mouse) IV Administration at 7 weeks showed correction in advanced heart failure Mice have developed significant cardiomyopathy at time of first injection at week 7 Significant and rapid improvement in treated arm vs. control ar
Slide 22: ANN-003 for Friedreich's Ataxia: Overview
ANN-003 for Friedreich's Ataxia: Overview Validated target: disease driven by mutation in single gene (FXN) AAV vector delivers FXN gene to cardiomyocytes to restore mitochondrial function Rationale for Gene Therapy Approach Pre-clinical POC established in robust cardiac mouse model Prevention of ca
Slide 23: Annapurna Pipeline in Detail
I. ANN-001 for α1 Antitrypsin Deficiency (A1AT) III. ANN-003 for Friedreich’s Ataxia (FA) ANN-004 for Severe Allergy II. ANN-002 for Hereditary Angioedema (HAE) Annapurna Pipeline in Detail
Slide 24: Severe Allergy Overview
Severe Allergy Overview Large unmet clinical need with no well established therapies Severe allergies cause discomfort and can be fatal Most common cause of anaphylaxis in children presenting to the ER Majority of fatalities due to accidental exposure in patients with known allergies No established
Slide 25: Anti-IgE antibody induces tolerance in clinical study
Anti-IgE antibody induces tolerance in clinical study Gene therapy delivery has potential for optimal exposure to ensure protection Dose dependent tolerance induction with anti-IgE antibody1 Patients tolerated < 1 peanut at baseline Patients tolerated >8 peanuts following anti-IgE therapy (450 mg q4
Slide 26: ANN-004 for Severe Allergy: Overview
ANN-004 for Severe Allergy: Overview Provide continuous levels of anti-IgE antibody to prevent severe reaction when patient exposed to allergen(s) Rationale for Gene Therapy Approach Clinical studies with anti-IgE antibody demonstrate induction of tolerance Protection demonstrated in fatal pre-clini
Slide 27: Wet AMD
Wet AMD
Slide 28: Wet AMD Gene Therapy: Next Steps
Wet AMD Gene Therapy: Next Steps Comprehensive pre-clinical wAMD research ongoing Seeking optimal vector, with optimal molecule utilizing best route of delivery Evaluating best path forward considering: Protein expression Consistent delivery Optimal method of administration Next generation vector te
Slide 29: Color Vision Deficiency Program
Color Vision Deficiency Program
Slide 30: AVA-322L and AVA-323M Product Overview for Color Vision Deficiency
AVA-322L and AVA-323M Product Overview for Color Vision Deficiency 1Sharpe LT, Stockman A, Jagle H, Nathans J. Opsin genes, photopigments, color vision and color blindness. In: Gegenfurtner KR, Sharpe LT (eds.) Color Vision. Cambridge UP: Cambridge, 1999. Intravitreal injection to confer better colo
Slide 31: Regeneron Collaboration
Regeneron Collaboration
Slide 32: Regeneron Collaboration (May 2014)
Regeneron Collaboration (May 2014) Covers up to eight distinct therapeutic targets AVA-311 for juvenile X-Linked Retinoschisis (XLRS) is first collaboration program REGN has chosen 3 other candidates that remain undisclosed Avalanche option to share up to 35% on profits and development costs for 2 t
Slide 33: AVA-311 Product Overview for XLRS
AVA-311 Product Overview for XLRS Potential long-term treatment of juvenile X-linked retinoschisis (XLRS) Optimized AAV vector delivers RS1 gene to maintain integrity of retina Rationale for Gene Therapy Approach High levels of RS1 protein expression in mouse model of XLRS Restoration of normal reti
Slide 34: Avalanche Financial Information
Avalanche Financial Information Basic Shares Outstanding (as of 1/28/16) New Basic Shares to be Issued in Transaction New Options to be Issued in Transaction Pro Forma Basic Shares Outstanding (as of 1/28/16) Pro Forma including Options, RSU’s and Warrants (TSM as of 1/28/16) Financial Information *
Slide 35: Post Merger Key Milestones
Post Merger Key Milestones Mid 2016 update on wet AMD program H2 2016 initiate enrollment of first-in-human trial of ANN-001 for A1AT deficiency H2 2016 provide guidance on ANN-003 timeline for Friedreich’s Ataxia 2016/2017 2017 patient enrollment for first-in-human study of ANN-002 for Hereditary A
Slide 36: Slide 36
Avalanche Biotechnologies — Merger or Acquisition (March 2016) on 6ix